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Highly networked signaling hubs are often associ-
ated with disease, but targeting them pharmacolog-
ically has largely been unsuccessful in the clinic
because of their functional pleiotropy. Motivated by
the hypothesis that a dynamic signaling code confers
functional specificity, we investigated whether
dynamic features may be targeted pharmacologi-
cally to achieve therapeutic specificity. With a virtual
screen, we identified combinations of signaling hub
topologies and dynamic signal profiles that are
amenable to selective inhibition. Mathematical anal-
ysis revealed principles that may guide stimulus-
specific inhibition of signaling hubs, even in the
absence of detailed mathematical models. Using
the NFkB signaling module as a test bed, we
identified perturbations that selectively affect the
response to cytokines or pathogen components.
Together, our results demonstrate that the dynamics
of signaling may serve as a pharmacological target,
and we reveal principles that delineate the opportu-
nities and constraints of developing stimulus-
specific therapeutic agents aimed at pleiotropic
signaling hubs.INTRODUCTION
Intracellular signals link the cell’s genome to the environment.
Misregulation of such signals often cause or exacerbate disease
(Lin and Karin, 2007; Weinberg, 2007) (so-called ‘‘signaling dis-
eases’’), and their rectification has been a major focus of
biomedical and pharmaceutical research (Cohen, 2002; Frelin
et al., 2005; Ghoreschi et al., 2009). For the identification of
therapeutic targets, the concept of discrete signaling pathways
that transmit intracellular signals to connect cellular sensor/
receptors with cellular core machineries has been influential. In448 Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc.this framework, molecular specificity of therapeutic agents
correlates well with their functional or phenotypic specificity.
However, in practice, clinical outcomes for many drugs with
highmolecular specificity has been disappointing (e.g., inhibitors
of IKK, MAPK, and JNK; Berger and Iyengar, 2011; DiDonato
et al., 2012; Ro¨ring and Brummer, 2012; Seki et al., 2012).
Many prominent signaling mediators are functionally pleio-
tropic, playing roles in multiple physiological functions (Chavali
et al., 2010; Gandhi et al., 2006). Indeed, signals triggered by
different stimuli often travel through shared network segments
that operate as hubs before reaching the effectors of the cellular
response (Bitterman and Polunovsky, 2012; Gao and Chen,
2010). Hubs’ inherent pleiotropy means that their inhibition
may have broad and likely undesired effects (Karin, 2008; Berger
and Iyengar, 2011; Force et al., 2007; Oda and Kitano, 2006;
Zhang et al., 2008); this is a major obstacle for the efficacy of
drugs targeting prominent signaling hubs such as p53, MAPK,
or IKK.
Recent studies have begun to address how signaling networks
generate stimulus-specific responses (Bardwell, 2006; Haney
et al., 2010; Hao et al., 2008; Zalatan et al., 2012). For example,
the activity of some pleiotropic kinases may be steered to partic-
ular targets by scaffold proteins (Park et al., 2003; Schro¨felbauer
et al., 2012; Zalatan et al., 2012). Alternatively, or in addition,
some signaling hubs may rely on stimulus-specific signal
dynamics to activate selective downstream branches in a
stimulus-specific manner in a process known as temporal or
dynamic coding or multiplexing (Behar and Hoffmann, 2010;
Chalmers et al., 2007; Hoffmann et al., 2002; Kubota et al.,
2012; Marshall, 1995; Purvis et al., 2012; Purvis and Lahav,
2013; Schneider et al., 2012; Werner et al., 2005).
Although the importance of signaling scaffolds and their
pharmacological promise is widely appreciated (Klussmann
et al., 2008; Zalatan et al., 2012) and isolated studies have
altered the stimulus-responsive signal dynamics (Purvis et al.,
2012; Park et al., 2003; Sung et al., 2008; Sung and Simon,
2004), the capacity for modulating signal dynamics for phar-
macological gain has not been addressed in a systematic
manner. In this work, we demonstrate by theoretical means
that, when signal dynamics are targeted, pharmacological
perturbations can produce stimulus-selective results. Specif-
ically, we identify combinations of signaling hub topology
and input-signal dynamics that allow for pharmacological per-
turbations with dynamic feature-specific or input-specific
effects. Then, we investigate stimulus-specific drug targeting
in the IKK-NFkB signaling hub both in silico and in vivo.
Together, our work begins to define the opportunities for phar-
macological targeting of signaling dynamics to achieve
therapeutic specificity.
RESULTS
Dynamic Signaling Hubs May Be Manipulated to Mute
Specific Signals
Previouswork has shown how stimulus-specific signal dynamics
may allow a signaling hub to selectively route effector functions
to different downstream branches (Behar et al., 2007). Here, we
investigated the capacity of simple perturbations to kinetic
parameters (caused for example by drug treatments) to produce
stimulus-specific effects. For this, we examined a simple model
of an idealized signaling hub (Figure 1A), reminiscent of the NFkB
p53 or ofMAPK signalingmodules. The hub X* reacts with strong
but transient activity to stimulus S1 and sustained, slowly rising
activity to stimulus S2. These stimulus-specific signaling
dynamics are decoded by two effector modules, regulating tran-
scription factors TF1 and TF2. TF1, regulated by a strongly adap-
tive negative feedback, is sensitive only to fast-changing signals,
whereas TF2, regulated by a slowly activating two-state switch,
requires sustained signals for activation (Figure 1B). We found it
useful to characterize the X*, TF1, and TF2 responses in terms of
two dynamic features, namely the maximum early amplitude
(‘‘E,’’ time < 150) and the average late amplitude (‘‘L,’’ 150 < t <
6 hr). These features, calculated using a mathematical model
of the network (see Experimental Procedures) show good fidelity
and specificity (Komarova et al., 2005) (Figure 1C), as S1 causes
strong activation of TF1 with minimal crosstalk to TF2, and vice
versa for S2.
Seeking simple (affecting a single reaction) perturbations that
selectively inhibit signaling by S1 or S2, we found that perturba-
tion A, partially inhibiting the activation of X, was capable of
suppressing hub activity in response to a range of S1 amplitudes
while still allowing for activity in response to S2 (Figure 1D).
Consequently, this perturbation significantly reduced TF1 activ-
ity in response to S1 but had little effect on TF2 activity elicited by
S2. We also found that the most effective way to inhibit S2
signaling was by targeting the deactivation of negative feedback
regulator Y (FBR). This perturbation caused almost complete
abrogation of late X activity yet allows for significant levels of
early activity. As a result, TF2 was nearly completely abrogated
in response to S2, but stimulus S1 still produced a solid TF1
response. The early (E) and late (L) amplitudes could be used
to quantify the input-signal-specific effects of these perturba-
tions (Figure 1E).
This numerical experiment showed that it is possible to
selectively suppress transient or sustained dynamic signals
transduced through a common negative-feedback-containing
signaling hub. Moreover, the dynamic features E and L could
be independently inhibited. To study how prevalent such oppor-tunities for selective inhibition are, we established a computa-
tional pipeline for screening reaction perturbations within multi-
ple network topologies and in response to multiple dynamic
input signals; the simulation results were analyzed to identify
cases of either ‘‘input-signal-specific’’ inhibition or ‘‘dynamic
feature-specific’’ inhibition (Figure 1F).
A Computational Screen to Identify Opportunities for
Input-Signal-Specific Inhibition
The computational screen involved small libraries of one- and
two-component regulatory modules and temporal profiles of
input signals (Figure 2A), both commonly found in intracellular
signaling networks. All modules (M1–M7, column on left) con-
tained a species X that, upon stimulation by an input signal,
is converted into an active form X* (the output) that propagates
the signal to downstream effectors. One-component modules
included a reversible two-state switch (M1) and a three-state
cycle with a refractory state (M2). Two-component modules
contained a species Y that, upon activation via a feedback
(M3 and M5) or feedforward (M4 and M6) loop, either deacti-
vates X (M3 and M4) or inhibits (M5 and M6) its activation.
We also included the afore-described topology that mimics
the IkB-NFkB or the Mdm2-p53 modules (M7). Mathematical
descriptions may be found in the Experimental Procedures.
Although many biological signaling networks may conform to
one of these simple topologies, others may be abstracted to
one that recapitulates the physiologically relevant emergent
properties.
The library of stimuli (S1–S10; Figure 2A, top row) comprises
ten input functions with different combinations of ‘‘fast’’ and
‘‘slow’’ initiation and decay phases (see Experimental Proce-
dures). The virtual screen was performed by varying the kinetic
parameter for each reaction over a range of values, thereby
modeling simple perturbations of different strengths and
recording the temporal profile of X* abundance. To quantify
stimulus-specific inhibition, we measured the area under the
normalized dose-response curves (time average of X* versus
perturbation dose) for each module-input combination (Experi-
mental Procedures, Figure 2B, and Figure S1 available online).
For many perturbations, we found doses that abrogated the
response to some inputs but not others (Figure S1). We also
observed that the responses to some input functions are
affected similarly in different modules (e.g., inputs S1 and S2,
both transient pulses), but others are not. For example, both
of the responses to inputs S8 and S1 are attenuated by the
IS (inhibitor strength) perturbation in M5, but FBA (feedback
activation) affects only the former. This indicates that the
capacity for selective inhibition is not intrinsic to the specific
dynamics of the input signal. Similarly, whereas some perturba-
tions targeting similar reactions in different topologies had
similar ‘‘dynamic footprints’’ (i.e., affecting responses to com-
mon sets of inputs, for example, feedforward activation [FFA]
in modules 4 and 6), most were less consistent and some
seemed to have opposite effects (activation [A] in M3/5 and
M4/6, for example).
Taken together, the results of this screen demonstrate that
perturbations with input-dynamics-specific effects are indeed
possible, but the specificity is dose and topology dependent.Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc. 449
Figure 1. Pharmacologic Perturbations with Stimulus-Specific Effects
(A) A negative-feedback module transduces input signals S1 and S2, producing outputs that are decoded by downstream effectors circuits that may distinguish
between different dynamics.
(B) Unperturbed dynamics of X*, TF1*, and TF2* in response to S1 (red) and S2 (blue). Definition of early (E) and late (L) parts of the signal is indicated.
(C) Specificity and fidelity of E and L for TF1* and TF2*, as defined in Komarova et al., 2005).
(D) Partial inhibition of X* activation (A) abolishes the response to S1, but not S2, whereas a perturbation targeting the feedback regulator (FBR) suppresses the
response to S2, but not S1.
(E) Perturbation phenotypes defined as difference between unperturbed and perturbed values of the indicated quantities (arbitrary scales for X*, TF1*, and TF2*).
Perturbation A inhibits E and TF1*, but not TF2*; perturbation FBR inhibits L and TF2*, but not TF1*.
(F) Virtual screening pipeline showing the experimental design and the two analysis branches for characterizing feature- and input-specific effects.
See also in Experimental Procedures and Table S1.Inhibition of Specific Dynamic Signaling Features
Applying the afore-described E (early maximum) and L (late
average)metrics,we foundsomeperturbations to have selectivity
for early (E) or late (L) phases of a signal (Figure 3A); for example,
FBRand to a lesser extent FFR (feedback and feedforward recov-
ery) consistently suppressed the late phase in a module- and450 Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc.largely input-independent manner (shown as the tangent angle
at the unperturbed point in the E-L space, Figure 3B, top). Others
were less consistent; for example, FBA and FFA tended to affect
early signalingor late signaling inan input-dependentbutmodule-
independent manner (Figure 3B, center). On the other hand, low-
dose perturbation of the activation reaction (A) inhibited primarily
Figure 2. A Virtual Screen for Stimulus Specificity in Pharmacologic Perturbations
(A) Signaling modules (left) and input library (top) used in the screen. Dotted lines indicate enzymatic reactions (perturbation names indicated in letter code). Time
courses of hub activity for each module/input combination for the unperturbed (black) and perturbed cases (blue indicates a decrease, red an increase in
parameter value).
(B) Relative sensitivity of the stimulus response to the indicated perturbation (defined as the perturbation’s effect on the area under the curve), normalized per row.
See also Experimental Procedures, Figure S1, and Tables S2 and S3.
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Figure 3. Inhibition of Specific Dynamic
Signaling Features
(A) Feature maps: effect of a perturbation on the
maximum early (t < 600) amplitude (y axis) and late
(600 < t < 300’) average amplitude (x axis) of the X*
response. Colored dots mark the unperturbed
response to indicated input signals, and curves
represent the responses for varying strengths of
the indicated perturbation.
(B) Tangent angle at the unperturbed point in the
E-L space (q < 0 E specificity, q > 0 L specificity)
(Top) Perturbation FBR (M3) suppresses late
signaling in an input-independent manner.
(Center) FFA attenuates early or late signaling in an
input-dependent manner. (Bottom) E-L specificity
switch for two doses of FBA (M3).
(C) Hierarchical clustering of the inhibitory effects
(left) related to the number of input signals
showing selective inhibition of early (blue), late
(yellow), or both (green) parts of the output. Bars
represent different perturbations doses.
See also Experimental Procedures and Figure S2.
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early signaling in the feedback-based modules (M3 and M5) and
late signaling in the feedforward-basedmodules (M4 andM6) but
only for some inputs. Interestingly, the specificity for E or L of
some perturbations may be reversed in different dosing regimes
(Figure 3B, bottom; note horizontal-vertical transition in the
corresponding panel in Figure 3A).
We then asked whether feature-specific inhibition correlated
with stimulus-specific inhibition. Hierarchical clustering the
perturbation data (Figure 3C) identified two major groups, char-
acterized by inhibition of the response to very brief (S1 and S2)
or sustained inputs. Comparing the clusters and the E or L
selectivity (determined from the angle in the E versus L space;
see Experimental Procedures and Figure S2) showed some
correlation between a perturbation’s E-L and stimulus speci-
ficity (Figure 3 C). We found that perturbations that affect the
late phase (e.g., FFR and FBR) affect signaling in response
to sustained inputs but had virtually no effect on the response
to S1 and S2. The reverse was less clear cut; perturbations
that tend to cause selective suppression of early phases could
have an effect on signals without strong early components as
well. We also observed that inputs that rise gradually (S7–
S10) tend to be more sensitive to inhibition than those that
rise quickly. However, these correlations are of limited predic-
tive value, as the same perturbation in the same module can
affect early signaling for some inputs but late signaling for
others. Moreover, E-L selectivity appeared dependent on
perturbation dose. Given the complexity of relating perturba-
tions with input and signal dynamics, we decided to study
the origin of the phenomenology observed in the screen using
the analytical tools of dynamical systems theory.
Phase Space Analysis Reveals Underlying Regulatory
Principles
To understand the origin of dynamic feature-specific inhibition,
we investigated the perturbation effects analytically on each
module’s phase space, i.e., the space defined by X* and Y*
quasi-equilibrium surfaces (Figures 4 and S4). These surfaces
(‘‘q.e. surfaces’’) represent the dose response of X* as a function
of Y* and a stationary input signal S (‘‘X surface’’) and the dose
response of Y* as a function of X* and S (‘‘Y surface’’) (Figure 4A).
The points at which the surfaces intersect correspond to the
concentrations of X* and Y* in equilibrium for a given value of
S. In the basal state, when S is low, the system is resting at an
equilibrium point close to the origin of coordinates. When S in-
creases, the concentrations of X* and Y* adjust until the signal
settles at some stationary value (Figure 4A). Gradually, changing
input signals cause the concentrations to follow trajectories
close to the q.e. surfaces (quasi-equilibriumdynamics), following
the line defined by the intersection of the surfaces (‘‘q.e. line’’)
in the extreme of infinitely slow inputs. Fast-changing stimuli
drive the system out of equilibrium, causing the trajectories to
deviate markedly from the q.e. surfaces.
Two main principles emerged: (1) perturbations that primarily
affect the shape of a q.e. surface tend to affect steady-state
levels or responses that evolve close to quasi-equilibrium, and
(2) perturbations that primarily affect the balance of timescales
(X*, Y* activation, and S) tend to affect transient out-of-equilib-
rium parts of the response. These principles reflect the factthat out-of-equilibrium parts of a signal are largely insensitive
to the precise shape of the underlying dose-response surfaces
(they may still be bounded by them) but depend on the
balance between the timescales of the biochemical processes
involved. Perturbation of these balances affects how a system
approaches steady state (thus affecting out-of-equilibrium and
quasi-equilibrium dynamics), but not steady-state levels. To
illustrate these principles, we present selected results for
modules M3 and M4 and discuss additional cases in the supple-
ment (Figure S3).
In the feedback-based modules (M3 and M5), the early
peak of activity in response to rapidly changing signals is an
out-of-equilibrium feature that occurs when the timescale of Y
activation is significantly slower than that of X. Under these
conditions, the concentration of X* increases rapidly (out of
equilibrium) before decaying along the X* surface (in quasi-
equilibrium) as more Y gets activated (Figure 4A, parameters
modified to better illustrate the effects being discussed; see
Table S2). For input signals that settle at some stationary level
of S, Y activation eventually catches up and the concentration
of X* settles at the equilibrium point where the X* and Y* curves
intersect. Gradually changing signals allow X* and Y* activation
to continuously adapt, and the system evolves closer to the
q.e. line.
In such modules, perturbation A (X* activation) changes both
the shape of the q.e. surface for X* and the kinetics of activation.
When in the unperturbed system Y* saturates, perturbation A
primarily reduces X* steady-state level (Figures 4B and 4C,
left and center). When Y* does not saturate in the unperturbed
system, the primary effect is the reduced activation kinetics.
Thus the perturbation affects the out-of-equilibrium peak (Fig-
ures 4B and 4C, center and right), with only minor reduction
of steady-state levels (especially when Y*’s dose response
respect to X* is steep). The transition from saturated to not-
saturated feedback (as well as the perturbation strength) under-
lies the dose-dependent switch from L to E observed in the
screen. In both saturated and unsaturated regimes, the shift in
the shape of the surfaces does change the q.e. line and thus
affects responses occurring in quasi-equilibrium. In contrast,
perturbation of the feedback recovery (FBR) shifts the Y* sur-
face vertically (Figure 4D), specifically affecting the steady-state
levels and late signaling; the effect on Y* kinetics is limited
because the reaction is relatively slow. Perturbation FBA
also shifts the Y* surface, but the net effect is less specific
because the associated increase in the rate of Y* activation
tends to equalize X* and Y* kinetics affecting also the out-of-
equilibrium peak.
In feedforward-based modules (e.g., M4), early signaling
peaks could arise also under quasi-equilibrium conditions
when X and Y have different dose-response curves for S
(observe the q.e. line in Figure 4E). In this module perturbation,
A (activation) primarily changes the shape of the X* surface,
affecting steady-state levels and quasi-equilibrium dynamics.
A perturbation dose sufficient to affect early signaling will also
completely suppress the late phase of the response, explaining
why, in contrast with feedback-based modules, perturbation A
in feedforward-based modules (M4 and M6) tended to affect pri-
marily late signaling.Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc. 453
Figure 4. Phase Space Analysis of Signaling
Modules’ Responses
(A) Quasi-equilibrium surfaces for X* (orange) and
Y* (green) as functions of stimulus strength s and
2D projections for low (sL) and high (sH) s levels in
feedback-based module M3. The time course of
X* in response to a fast (red) and slow gradual
(blue) input are indicated. Strict quasi-steady
response is shown in black.
(B) Effect of perturbation A in negative feedback
module M3. The arrow indicates whether the
perturbation suppresses (–) or enhances (+) the
reaction.
(C) Cross-sections of the X* and Y* (orange and
green) surfaces for low and high S and the pro-
jection of the time-course concentrations of X*-Y*
for fast and gradually changing signals (red/blue).
Projection of the q.e. line is indicated with a
dashed black line. Corresponding time courses
are shown on the right (top-most curve corre-
sponds to higher values of parameter). The
perturbation primarily affects steady-state levels
(transition from left to center panels when the
feedback saturates and out-of-equilibrium and
quasi-equilibrium dynamics otherwise (transition
from center to right panels).
(D) Effect of perturbation FBR in negative feed-
back module M3.
(E and F) (E) Effect of perturbation A on incoherent
feed-forward loop M4, and (F) the corresponding
two-dimensional projections. Note how the inter-
section (black line) of the surfaces defines a peak
of activity
See also Figure S3 and Table S4.These dynamic response principles (summarized in Table S4)
link a perturbation’s feature and stimulus specificity. While with
simple perturbations, effects on dose response and kinetics
are linked, the particular parameters determine which effect is
dominant. Here, we have explicitly considered responses to454 Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc.input signal activation, but the same prin-
ciples apply to input termination. In those
cases, specificity may arise from differ-
ences in the decay rate of the input.
Manipulating Specific Dynamic
Features of NFkB Signaling
The IKK-IkB-NFkB signaling module
functions as a signaling hub for diverse in-
flammatory, immune, and developmental
signals (Hoffmann and Baltimore, 2006).
Its activity is regulated in a stimulus-
specific manner, and stimulus-specific
dynamic control of the input kinase IKK
was shown to mediate stimulus-specific
gene expression programs (Hoffmann
et al., 2002; Werner et al., 2005). We
examined here how the principles out-
lined above could be applied to design
pharmacological perturbations causingstimulus-specific inhibition of NFkB. We focused on NFkB
dynamics typically triggered by tumor necrosis factor (TNF), a
proinflammatory cytokine that may mediate chronic (TNFc)
or pulse (TNFp) stimulation, and lipopolysaccharide (LPS), a
component of Gram-negative bacteria.
Figure 5. Modulating NFkB Signaling
Dynamics
(A) The IkB-NFkB signaling module.
(B) Equilibrium dose-response relationship for
NFkB versus IKK.
(C) Three IKK curves representative of three
stimulation regimes; TNFc (red), TNFp (green), and
LPS (blue) function as inputs into the model, which
computes the corresponding NFkB activity dy-
namics (bottom). The quasi-equilibrium line (black)
was obtained by transforming the IKK temporal
profiles by the dose response in (B). Deviation from
the quasi-equilibrium line for the TNF response
indicates out-of-equilibrium dynamics.
(D) Coarse-grainedmodel of the IkB-NFkBmodule
and predicted effects of perturbations.
(E) Selected perturbations with specific effects on
out-of-equilibrium (top three) or steady state
(bottom two). (Left to right) Featuremaps in the E-L
space (E: t < 60 0, L: 1200 < t < 3000), tangent angle
at the unperturbed point (q > 0 indicates L is more
suppressed than E and vice versa), and time
courses (green, TNF chronic; red, TNF pulse; blue,
LPS). Only inhibitory perturbations are shown.
Additional perturbations are shown in Figure S4.
See also Experimental Procedures and Table S7.In resting cells, NFkB is held inactive through its association
with inhibitors IkBa, b, and ε. Upon stimulation, these proteins
are phosphorylated by the kinase IKK triggering their degrada-
tion. Free nuclear NFkB activates the expression of target genes,
including IkB-encoding genes, which thereby provide negative
feedback (Figure 5A). The IkB-NFkB-signaling module is a com-
plex dynamic system; however, by abstracting the control mech-
anism to its essentials, we show below that the above-described
principles can be applied profitably.
We begin by determining whether NFkB activation proceeds
out of or in quasi-equilibrium, using an experimentally validatedCell 155, 448–461,computational model (Werner et al.,
2005) and temporal profiles of IKK inputs
determined experimentally for the condi-
tions under consideration. For this, we
compared the time-dependent concen-
tration of nuclear NFkB with that ex-
pected if, at each time point, the network
was in equilibrium with the instant IKK
activity level (Figures 5B and 5C). Devia-
tions during the early phase of the TNF
response indicated that it occurs out of
equilibrium, whereas the response to
LPS evolves close to quasi-equilibrium.
Under these conditions, our findings
suggest that it may be possible to selec-
tively attenuate the out-of-equilibrium
(early) or steady-state (late) phase of the
TNF and LPS response. Selective attenu-
ation of out-of-equilibrium dynamics re-
quires a perturbation that equalizes the
activation and feedback timescaleswithout substantially reshaping the dose-response relationships.
Conversely, attenuation of steady-state levels and quasi-
equilibrium dynamics requires perturbations that alter the
dose-response relationships without substantially affecting the
balance of timescales. We compared the essential control
mechanisms of the IkB-NFkB signaling module (Figure 5D, left)
with module M3 studied above to infer the effect of perturbations
(Figure 5D). We estimated that perturbations classified as A
(inhibition of activation), such as inhibition of IKK-mediated IkB
degradation or free NFkB nuclear import, would primarily affect
timescales and therefore out-of-equilibrium dynamics. TheseOctober 10, 2013 ª2013 Elsevier Inc. 455
perturbations show E-L switch behavior (Figure 3), but because
feedback is not saturated (enough IkB can be produced), we
expect them to affect out-of-equilibrium dynamics. In contrast,
perturbations classified as IS (inhibitor strength), such as
inhibition of IkB import, would unlikely affect the balance of
timescales, as the feedback timescale is dominated by slow
de novo protein production. On the other hand, we expected
perturbations that enhance the feedback without substantially
altering its timescale to cause a reduction in steady-state
levels and late signaling. Partial inhibition of the feedback
recovery (FBR) proved very selective before, suggesting stabili-
zation of IkB mRNA, or the protein itself may selectively atten-
uate the late component of the TNFc response and the LPS
response.
We next used the detailed mathematical model to test the pre-
dictions (Figures 5E and S4). We found that partial inhibition of
NFkB nuclear import or IkBa degradation (Figure 5E, top) at
some doses affected out-of-equilibrium dynamics, attenuating
the response to TNFp and the initial peak of the response to
TNFc. The response to LPS was delayed but less impacted in
terms of sustained amplitude. Unexpectedly, partial inhibition
of nuclear export of the NFkB-IkB complex or stabilization of
free IkBa produced similar effects. Further analysis revealed
that, in this network, both perturbations effectively act as activa-
tion inhibitors: the former causes initial accumulation of the inac-
tive NFkB-IkB complex in the nucleus from which it cannot be
directly activated (IKK is cytosolic), whereas the latter generates
a basal excess of IkBa that must be degraded before nuclear
translocation of NFkB can proceed. Perturbations affecting the
timescale of the feedback (e.g., increase of mRNA production
rate) were less selective, probably due to the changes that
they introduced in the IKK-IkB-NFkB dose-response relation-
ships. Simulations also confirmed that partial inhibition of IkBa
mRNA degradation (protein stabilization affects early signaling
as discussed above) attenuates the late phase of the TNFc
response and suppresses the response to LPS (Figure 5E, bot-
tom), although with some collateral attenuation of the early
phase as well. Conversely, destabilization of IkBmRNA impaired
postinduction attenuation and significantly extended the
response to TNFp. Finally, enhancement of IkBε mRNA produc-
tion suppresses late TNF-induced signaling in a specific manner.
This specificity arises from the delay (45 0) associated with the
induction of this gene (Kearns et al., 2006), which also explains
why the response to LPS is not affected until late during the
signaling event.
The above principles identify conditions necessary but not
necessarily sufficient for the existence of perturbations with
dynamics and, by extension, stimulus-specific effects. Even
though the specific effects attained in the IkB-NFkB module
are partial (compared to the idealized cases in Figure 4), they
demonstrate that perturbations with stimulus-specific effects
are indeed feasible within that signaling module.
Targeting the NFkB-Signaling Hub to Achieve Stimulus-
Specific Inhibition
To develop experimentally testable predictions, we simulated
the effect of actual pharmacological agents. We focused on
agents that target known but ubiquitous biochemical mecha-456 Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc.nisms (as do some successful therapeutic agents such as as-
pririn or bortezomib) to test whether they could nevertheless
have stimulus-specific effects. Computationally, we simulated
the effect of each drug at 11 doses and 3 times of administration
and used the feature metric for early and late phases to select
treatment conditions from the resulting data set that had
stimulus-specific effects (Experimental Procedures). These pre-
dictions were tested experimentally in cultures of primary
fibroblasts, preparing nuclear extracts and mRNAs at specific
time points for subsequent assays of DNA-binding activity and
target gene expression. We found that cotreatment with the
general translation inhibitor cycloheximide (inhibits IkB synthe-
sis) preferentially affected TNFp-responsive signaling, resulting
in higher target gene expression (Figure 6A, middle), whereas
pretreatment with this inhibitor affected NFkB signaling in
response to all stimuli (Figure 6A, right). Similarly, whereas low
doses of the antioxidant pyrrolidine dithiocarbamate (PDTC)
(Brennan and O’Neill, 1996), a drug that inhibits NFkB-induced
transcription, inhibited NFkB induction and target gene expres-
sion by LPS, high doses abrogated signaling in response to all
stimuli (Figure 6B). Interestingly, the general proteasome inhibi-
tor MG132 (inhibits IkB degradation) was predicted to specif-
ically inhibit late-phase TNFc and LPS-induced NFkB activity
but with little effect on early responses characteristic of TNFp
stimulations (Figure 6C, middle). Consistent with this observa-
tion, the expression of the nfkbie gene that is typically induced
in the hour timescale was abrogated by this treatment. In
contrast postinduction attenuation of NFkBn, a hallmark of
TNF stimulation, was impaired by treatment with the HDAC in-
hibitor trichostatin A (TSA), a general inhibitor of transcription
(and therefore IkB synthesis), whereas LPS-induced NFkB activ-
ity was barely affected.
DISCUSSION
Here, we delineate the potential of achieving stimulus-specific
inhibition when targeting molecular reactions within pleiotropic
signaling hubs. We found that it is theoretically possible to
design perturbations that (1) selectively attenuate signaling in
response to one stimulus but not another, (2) selectively atten-
uate undesirable features of dynamic signals or enhance desir-
able ones, or (3) remodulate output signals to fit a dynamic profile
normally associated with a different stimulus.
These opportunities—not all of them possible for every
signaling module topology or biological scenario—are governed
by two general principles based on timescale and dose-
response relationships between upstream signal dynamics and
intramodule reaction kinetics (Figure 4 and Table S4). In short,
a steady-state or quasi-equilibrium part of a response may be
selectively affected by perturbations that introduce changes in
the relevant dose-response surfaces. Out-of-equilibrium re-
sponses that are not sensitive to the precise shape of a dose-
response curve may be selectively attenuated by perturbations
that modify the relative timescales. Dose responses and time-
scales cannot, in general, be modified independently by simple
perturbations (combination treatments are required), but as we
show, in some cases, one effect dominates resulting in feature
or stimulus specificity.
Figure 6. Stimulus-Specific Pharmacological Perturbations of NFkB Signaling
(A–C) Simulated and observed effects of pharmacological inhibitors on NFkB activity. Leftmost bar graph panels show NFkB activity predicted at indicated time
points in MEFs in response to TNFc (red), TNFp (green), and LPS (blue) in the absence of pharmacologic inhibitors. Center and right bar graphs show
computational predictions in response to the same stimuli under drug treatments. Asterisks indicate effects greater than 2-fold thought to be experimentally
detectable. (Top rows of gel images) Electrophoretic mobility shift assays (EMSAs) of NFkB activity. (Bottom gel images) RNase Protection analysis (RPA)
revealing the effect on the indicated NFkB target genes.
See also Figure S5 and Table S7.The degree to which specific dynamic features of a signaling
profile or the dynamic responses to specific stimuli can be selec-
tively inhibited depends on how distinctly they rely on quasi-
equilibrium and out-of-equilibrium control. Signals that contain
both features may be partially inhibited by both types of pertur-
bation, limiting the specific inhibition achievable by simple per-
turbations. In practice, this limited the degree to which NFkB
signaling could be inhibited in a stimulus-specific manner (Fig-
ure 5) and the associated therapeutic dose window (Figure 6).
The most selective stimulus-specific effects can be introduced
when a signal is heavily dependent on a particular dynamicfeature; for example, suppression of out-of-equilibrium tran-
sients will abrogate the response to stimuli that produce such
transients. For a selected group of target genes, this specificity
at the signal level translated directly to expression patterns (Fig-
ure 6B, middle). More generally, selective inhibition of early or
late phases of a signal may allow for specific control of early
and late response genes (Figure 6C), a concept that remains to
be studied at genomic scales. Though the principles are general,
how they apply to specific signaling pathways depends not only
on the regulatory topology, but also on the dynamic regime
determined by the parameters. As demonstrated with theCell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc. 457
Figure 7. Timescales of Cellular Processes Relevant for Signaling
Order of magnitude timescales associated with intracellular processes that
can be combined to produce complex signaling networks. Combinations of
processes with different timescales can result in responses with significant
out-of-equilibrium components, whereas similar timescales will likely produce
quasi-equilibrium dynamics. The timescale difference must be considered in
relation to the timescale at which the input signal changes.IkB-NFkB module, analysis of a coarse-grained topology in
terms of the principles may allow the prediction of perturbations
with a desired specificity. Although not studied here, we believe
it is possible to exploit features such as multistability and sus-
tained oscillations to introduce specific effects based on fre-
quency discrimination or through selective alteration of specific
stable states. Which dynamic feature to target depends on the
downstream effector modules that decode the hub’s dynamic
activity and thus determine which dynamic feature is physiolog-
ically relevant (Behar and Hoffmann, 2010; Purvis and Lahav,
2013). While we employed simple examples of such decoding
circuits in Figure 1 that informed our selection of E and Lmetrics,
future studies (both theoretical and experimental) may uncover
diverse topologies and decoding properties that could substan-
tially extend the present work.
The timescales associated with signaling processes (Figure 7)
suggest that some aremore likely to generate kinetic imbalances
that could lead to out-of-equilibrium response dynamics and
thus opportunities for achieving specificity based on signaling
dynamics. For example, because activation and deactivation
mechanisms based on posttranslational modifications are typi-
cally fast (in the subsecond to second regime), they are more
likely to determine dose-response relationships than out-of-
equilibrium transients. On the other hand, mechanisms involving
protein synthesis and protein degradation are slower (in the sub-
hour to hour regime) and are therefore more likely to cause
out-of-equilibrium dynamic features and thus provide for oppor-
tunities for selective drug targeting. The recycling motif (M2),
relevant to receptors (Becker et al., 2012) or kinases (Behar458 Cell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc.and Hoffmann, 2013), can respond with out-of- or quasi-equilib-
rium signals, depending on the specific kinetic rates (Behar and
Hoffmann, 2013). In summary, knowing the molecular processes
that regulate hub activity can provide clues about signal dynamic
features and potential perturbation strategies.
Our results warrant a number of other observations. First, the
pharmacologic interventions discussed here do not require full
inhibition of the target. In fact, strong inhibition is undesirable,
as it suppresses signaling wholesale and tends to degrade the
dynamics selectivity. Thus, drug candidates that are too weak
to be deemed suitable for therapeutic use could become viable
for therapeutic applications based on signal dynamics. This
could also allow for lower concentrations, potentially mitigating
side effects due to a drug’s polypharmacological footprint (Force
et al., 2007; Ma’ayan et al., 2007). Second, perturbations often
remain relatively selective for a given dynamic feature or signal
input family over a range of doses (often by an order of magni-
tude or more). This implies that robust effects could be achieved
over a wide therapeutic window (notice the pronounced horizon-
tal or vertical segments in Figure 3A). Third, pharmacological
intervention does not need to occur concurrently with the stim-
ulus. Thus, particularly for stimuli or conditions involving only
short term signaling, the design of perturbations targeting
signaling dynamics is largely decoupled from the pharmacody-
namic problem. Fourth, what is most relevant for the control of
a dynamic signaling feature is the timescale on which a ‘‘pro-
cess’’ operates and the shape of the overall dose-response
curves. As processes comprise multiple reactions, the result is
an expanded list of potential targets. This is exemplified by the
role of IkB stability as part of the NFkB ‘‘activation’’ process, in
which both IkB degradation and NFkB import reactions emerged
as targettable. Taken together, these findings mean that, once
the corresponding target processes are identified, there could
be a large window of opportunity for finding suitable pharmaceu-
tical approaches for which coarse tuning may suffice. Further,
these considerations may suggest a two-step strategy for phar-
macological targeting of signaling hubs: first, using a coarse-
grained model of regulatory processes to identify opportunities
for pharmacological intervention, and second, developing a
detailed mechanistic reaction model of the key process(es) to
be targeted to identify actual molecular drug targets with desired
effects.
The approach described here can be used to devise strategies
for selective control of signals that are relevant for particular
biological or pathological scenarios even in the absence of a
detailed mathematical model. In systems in which temporal con-
trol is suspected, the principles outlined here can be used to
guide pharmacological design on a trial-and-error basis with
signal dynamics as the readout. In this sense, signal dynamics
per se (not the signal transducer) may be treated as a pharmaco-
logical target.EXPERIMENTAL PROCEDURES
Primary mouse embryonic fibroblasts (MEFs) were prepared, cultured, and
stimulated as described (Werner et al., 2005), using either 0.1 mg/ml LPS
(Sigma, B5:055) or 1 ng/ml murine TNF (Roche) for the duration of the time
course (chronic, TNFc) or transiently for 45min (pulse, TNFp). Pharmacological
inhibitors (cycloheximide (CHX, Sigma), MG132 (Calbiochem), pyrrolidine
dithiocarbamate (PDTC, Sigma), or trichostatin A (TSA, Wako Chemicals)
were administered at the concentration indicated 2 hr prior to or coin-
cident with TNF or LPS. Electrophoretic mobility shift assays (EMSA) and
RNase protection assays (RPA) were performed as described (Werner et al.,
2005).
Simple Computational Model
The network in Figure 1 was modeled as in Equations 1–5.
d½X
dt
=
k1,s,ð1 ½XÞ
km1 + ð1 ½XÞ 
k2b,½X,½Y
km2b + ½X  k2a,½X
 (Eq. 1)
d½Y
dt
=
k3,½X,ð1 ½YÞ
km3 + ð1 ½YÞ 
k4,½Y
km4 + ½Y (Eq. 2)
d½TF1
dt
= k6,ð1 ½TF1Þ  k7a,½TF1  k7b,½TF1½W (Eq. 3)
d½W
dt
=
k8,½TF1,ð1 ½WÞ
km8 + ð1 ½WÞ 
k9,½W
km9 + ½W (Eq. 4)
d½TF2
dt
= k5að1 ½TF2Þ  k5b½TF2 (Eq. 5)
Parameters (perturbed and unperturbed) are given in Table S1. Input s was
replaced with the functions in Equations 6 and 7 (representing S1 and S2,
respectively) with parameters: sl = 0, sb = 0.0001, sh = 1, tr = 0.1, td = 0,
tp1 = 0.5, j = 30, h = 0.0085.F1ðtÞ= j sb t%tdsb+ ðt  tdÞshtr td%t<tr + tdsb+ sh tr + td%t<tp1+ tr + tdsbase+ sh ðt  tp1 tr  tdÞðsh slÞ
tc
tp1+ tr + td%t<tp1+ tr + tc+ td
sb+ sl tp1+ tr + tc+ td<t
(Eq. 6)F2ðtÞ= j sb t<tdsbð1+ jÞ+ ð10ttdÞh  1
j + ð10ttdÞh tRtd
(Eq. 7)
We used the definition of specificity and fidelity in Komarova et al. (2005)
(Equations 8–11).
STF1 =
TF1jS1
TF2jS1;STF2 =
TF2jS2
TF1jS2 (Eq. 8, 9)
FTF1 =
TF1jS1
TF1jS2;FTF2 =
TF2jS2
TF2jS1 (Eq. 10, 11)
The quantity TFxjSy is TFx activity (early or late as, defined in the text) in
response to stimulus Sy.Virtual Screen and Phase Space Analysis
The modules in the virtual screen were modeled with ordinary differential
equations using kinetic laws of the form VA, VAI, VD, VDF, and VMA (Equations
12–17).
VA =
k1,s,½X
km1 + ½X; VAI =
k1,s,½X
km1 + k2i½Y (Eq. 12, 13)
VD =
k2a,½X
km2 + ½X; VDF =
k2b,½Y,½X
km2 + ½X ; VDMA = k2a,½X
 (Eq. 14-15)
VFB =
k3,½X,½Y 
km3 + ½Y  ; VFF =
k3,s,½Y 
km3 + ½Y ; VFR =
k4,½Y
km4 + ½Y (Eq. 16-17)
In all cases, the species were conserved and the total concentration normal-
ized to 1. For the cycle motif, the activation proceeded as in the previous
cases, but species X* had to undergo deactivation to a refractory species
X, which in turn was recycled back to X (Equation 18).
VR =
k3,½X
km3 + ½X (Eq. 18)
Module equations:
M1: ½X0 =VA  VD (Eq. 19)
M2: ½X0 =VA  VD (Eq. 20)
M3: ½X0 =VA  VDMA  VDF; ½Y
0
=VFB  VFR (Eq. 21)M4: ½X0 =VA  VDMA  VDF; ½Y
0
=VFF  VFR (Eq. 22)M5: ½X0 =VAI  VD; ½Y
0
=VFB  VFR (Eq. 23)
M6: ½X0 =VAI  VD; ½Y
0
=VFF  VFR (Eq. 24)
M7: ½X0 = k1,½X
km1 + ½X 
k2i,½X,½Y 
km2i + ½X  VD; ½Y
0 = k3,s,½Y 
km3 + ½Y 
 k4,½X
,½Y
km4 + ½Y
(Eq. 25)
The rates for the activation reactions were tuned so they all respond on
similar timescales. Negative regulation was set to operate slower to generate
a wider range of dynamics. The timescale was chosen to be slower than theCell 155, 448–461, October 10, 2013 ª2013 Elsevier Inc. 459
initial increase rate for ‘‘fast’’ inputs (e.g., S1) but faster than the rate corre-
sponding to gradual inputs (e.g., S8). The Michaelis constants were set to
10% of the total concentration of the corresponding species to represent
enzymatic reactions with saturation. The EC50 for the modules was set to
roughly correspond to 1 unit of s in order to allow suppression but also
enhancement of the responses. Perturbations were simulated by applying
multipliers to the kinetic parameters (Table S2). The input curves were
generated according to Equations 6 (stepwise) and 7 (sigmoid) with parame-
ters in Table S3.
The global metric (Figure 2A) was calculated as follows: for a given module-
perturbation-input signal combination, we calculated the area under the curve
(AUC) for the X* time course for each perturbation dose. We then generated a
dose-response curve for AUC (normalized to the unperturbed value) versus
perturbation dose (Figure S1). The relative effect of a perturbation was quanti-
fied as the area under the dose-response curves corresponding to different
inputs. A smaller number represents higher sensitivity. For Figure 2, the metric
was inverted (brighter colors indicate higher sensitivity) and normalized within
each row. This data set was clustered using the function ‘‘DendogramPlot’’
(Mathematica, version 8, Wolfram, Urbana-Champaign, IL) with Euclidean
distance andWard linkage. Selectivity for early or late signaling was quantified
by the angle Q in the E-L space (Figures 3A and S2). We excluded doses that
did not substantially change the response (Euclideandistance in theE-Lplane<
0.1) and classified the rest as E (QR 15), L (Q% 15), or both (15 <Q< 15).
NFkB Signaling Hub
The mass action kinetic model of the NFkB signaling module was taken from
an updated version of that in Werner et al. (2005) See Figure S5 for diagram
and Table S5 for reactions and parameters. Themodel was equilibrated before
applying the IKK activity profiles (Table S6). Perturbations were simulated by
applying a range of multipliers to groups of related parameters (Table S7).
For modeling the effects of pharmacological inhibitors on the response to
LPS stimulation (Figures 5B–5D), a simple model to account for TNF feedback
was introduced, parameterized by the measured IKK activity profiles in TNF
knockout cells (Werner et al., 2005). Specifically, ‘‘TNF’’ is synthesized in an
NFkB-dependent manner (0.4 min1), is added to the IKK scaling factor, and
is degraded (0.3 min1). To simulate pharmacological perturbations, parame-
ters were grouped as described in Table S7 andwere altered over a wide range
(100.0625–102) in three treatment regimens: pretreatment (during equilibra-
tion phase), cotreatment (at start of signaling phase), and posttreatment
(at t = 60 min).
Simulation and analysis were performed with the package Mathematica 8
(Wolfram, Urbana-Champaign, IL) except for the pharmacological simulations
performed with the package MatLab R2007a (The Mathworks, Natick, MA).
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